bluebird bio, Inc. Common Stock

BLUE Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Ownership

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
BLUE Income Statement
BLUE Balance Sheet
BLUE Cash Flow
Congress Trading

Recent trades of BLUE by members of U.S. Congress

Politician Type Traded
Lois Frankel House / D Sale $1,001 - $15,000 Dec. 11, 2020
Lois Frankel House / D Sale $1,001 - $15,000 Dec. 10, 2020
Lois Frankel House / D Purchase $1,001 - $15,000 Jul. 15, 2020
Lois Frankel House / D Purchase $1,001 - $15,000 Apr. 27, 2020
BLUE Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
BLUE Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
BLUE Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by BLUE's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $90,000 Nov 07, 2024 Issue: Medicare/Medicaid Health Issues
  • $60,000 Oct 18, 2024 Issue: Health Issues Medicare/Medicaid
  • $210,000 Apr 19, 2024 Issue: Medicare/Medicaid Health Issues
  • $140,000 Apr 04, 2024 Issue: Health Issues
  • $150,000 Nov 09, 2023 Issue: Health Issues
  • $80,000 Oct 18, 2023 Issue: Health Issues
  • $20,000 Jul 20, 2022 Issue: None
  • $170,000 Apr 19, 2022 Issue: Health Issues
  • $100,000 Apr 19, 2022 Issue: Health Issues
  • $170,000 Oct 20, 2021 Issue: Health Issues
  • $50,000 Jul 20, 2021 Issue: Medicare/Medicaid Government Issues Health Issues Budget/Appropriations
  • $60,000 Jul 20, 2021 Issue: Health Issues
  • $30,000 Jul 14, 2021 Issue: Health Issues Medicare/Medicaid
  • $100,000 Mar 10, 2021 Issue: None
  • $180,000 Jan 20, 2021 Issue: None
  • $200,000 Oct 20, 2020 Issue: None
  • $180,000 Jul 20, 2020 Issue: None
  • $220,000 Apr 17, 2020 Issue: None
  • $280,000 Jan 21, 2020 Issue: None
  • $140,000 Oct 18, 2019 Issue: Health Issues Medicare/Medicaid
  • $150,000 Jul 22, 2019 Issue: Medicare/Medicaid Health Issues
  • $10,000 May 03, 2019 Issue: Health Issues
  • $60,000 Apr 19, 2019 Issue: Budget/Appropriations Medicare/Medicaid Health Issues
  • $10,000 Jan 23, 2019 Issue: Health Issues
  • $60,000 Jan 18, 2019 Issue: Medicare/Medicaid Health Issues
  • $10,000 Oct 25, 2018 Issue: Health Issues
  • $60,000 Oct 22, 2018 Issue: Medicare/Medicaid Health Issues
  • $10,000 Jul 25, 2018 Issue: Health Issues
  • $60,000 Jul 20, 2018 Issue: Health Issues Medicare/Medicaid
  • $20,000 Apr 20, 2018 Issue: Health Issues
  • $60,000 Apr 20, 2018 Issue: Medicare/Medicaid Health Issues
  • $60,000 Jan 22, 2018 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
  • $23,000 Jan 22, 2018 Issue: Health Issues
  • $26,000 Oct 23, 2017 Issue: Health Issues
  • $60,000 Oct 19, 2017 Issue: Medicare/Medicaid Health Issues
  • $60,000 Jul 19, 2017 Issue: Health Issues Medicare/Medicaid
  • $6,000 Jul 19, 2017 Issue: Health Issues
  • $6,000 Apr 20, 2017 Issue: Health Issues
  • $60,000 Apr 19, 2017 Issue: Budget/Appropriations Health Issues Medicare/Medicaid
  • $6,000 Jan 24, 2017 Issue: Health Issues
  • $60,000 Jan 18, 2017 Issue: Health Issues
  • $60,000 Oct 20, 2016 Issue: Health Issues
  • $60,000 Jul 18, 2016 Issue: Health Issues
Corporate Lobbying

Estimated quarterly lobbying spending

U.S. Patents

New patents grants

  • Patent Title: Compounds for improved viral transduction Dec. 05, 2023
  • Patent Title: Therapeutic retroviral vectors for gene therapy Jul. 18, 2023
  • Patent Title: Sickled beta globin antibodies Dec. 27, 2022
  • Patent Title: Vcn enhancer compositions and methods of using the same May. 10, 2022
  • Patent Title: Vectors and compositions for treating hemoglobinopathies Mar. 01, 2022
  • Patent Title: Bcma chimeric antigen receptors Jun. 01, 2021
  • Patent Title: Cblb endonuclease variants, compositions, and methods of use Feb. 23, 2021
  • Patent Title: Compounds for improved viral transduction Feb. 02, 2021
  • Patent Title: Cblb endonuclease variants, compositions, and methods of use Oct. 06, 2020
  • Patent Title: Mnd promoter chimeric antigen receptors Sep. 15, 2020
  • Patent Title: Bcma chimeric antigen receptors May. 12, 2020
  • Patent Title: Bcma chimeric antigen receptors May. 05, 2020
  • Patent Title: Bcma chimeric antigen receptors May. 05, 2020
  • Patent Title: Bcma chimeric antigen receptors Mar. 03, 2020
  • Patent Title: Bcma chimeric antigen receptors Mar. 03, 2020
  • Patent Title: Compounds for improved viral transduction Dec. 10, 2019
  • Patent Title: Methods of making t cell compositions Nov. 19, 2019
  • Patent Title: Multipartite signaling proteins and uses thereof Oct. 29, 2019
  • Patent Title: Multipartite signaling proteins and uses thereof Oct. 01, 2019
  • Patent Title: Bcma chimeric antigen receptors Aug. 20, 2019
  • Patent Title: Gene therapy methods May. 07, 2019
  • Patent Title: Multipartite signaling proteins and uses thereof Feb. 05, 2019
  • Patent Title: Therapeutic retroviral vectors for gene therapy Oct. 23, 2018
  • Patent Title: Compounds for improved viral transduction Jun. 05, 2018
  • Patent Title: Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy Oct. 17, 2017
  • Patent Title: Gene therapy methods Oct. 10, 2017
  • Patent Title: Therapeutic retroviral vectors for gene therapy Jun. 30, 2015
  • Patent Title: Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy Jun. 23, 2015
  • Patent Title: Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy Oct. 14, 2014
  • Patent Title: Lentiviral packaging cells and uses therefor Oct. 11, 2011
  • Patent Title: Therapeutic retroviral vectors for gene therapy Mar. 08, 2011
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded from public contracts

WallStreetBets

Number of mentions of BLUE in WallStreetBets Daily Discussion

BLUE News

Recent insights relating to BLUE

CNBC Recommendations

Recent picks made for BLUE stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in BLUE

BLUE Top Shareholders
Shareholder
Shares Held
BLUE Options Owners
Shareholder
Security
Underlying Shares

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

BLUE Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view BLUE Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top